ArticleEClinicalMedicine2022

Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).

Francisco Hernández-Bernal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.